Print Page  Close Window

Press Release

Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors

CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced the election of John A. Hohneker, M.D., Executive Vice President, Head of Research and Development of FORMA Therapeutics Inc., to Dimension’s Board of Directors (the “Board”). Dr. Hohneker brings over 25 years’ global experience in pharmaceutical drug development across diverse therapeutic areas to address substantial unmet needs. His election to the company’s Board is effective immediately.

“John is a highly accomplished leader in the biopharma industry, and we are pleased to welcome him to Dimension’s Board,” said Dr. Annalisa Jenkins, MBBS, FRCP, Chief Executive Officer of Dimension. “John offers broad experience developing therapeutics from preclinical testing through health authority approval across multiple therapeutic areas, including 17 drug launches. We expect his expertise will contribute greatly to the continued progress of our clinical and preclinical stage pipeline.”

“John has built high-performing teams and successfully developed multiple ground-breaking medicines that have had a profound impact on global human health,” stated Rishi Gupta, JD, Private Equity Partner at OrbiMed and Chairman of Dimension’s Board. “His perspectives and insight will have an important impact as Dimension’s novel product portfolio further progresses into and through the clinic.”

Dr. Hohneker stated, “Dimension is developing therapies with the potential to transform the treatment of rare, metabolic diseases associated with the liver, which often have devastating outcomes for patients and their families. I look forward to contributing to the company’s advancement of these promising product candidates in the clinic.”

Most recently, Dr. Hohneker has guided FORMA’s transition from the discovery stage to a company with programs in clinical trials. Prior to this, he held leadership positions at Novartis, including as Senior Vice President and Global Head of Development, Immunology and Dermatology, in which role he was responsible for the global development of the company’s immunology, rheumatology, and dermatology product pipelines. During his tenure at Novartis, Dr. Hohneker played a key role in the development, approval, and/or commercialization of products including Cosentyx®, Xolair®, Ilaris®, Gleevec®, Tasigna®, Zometa®, Afinitor®, and Exjade®. Previously, Dr. Hohneker held various roles of increasing responsibility at Glaxo Wellcome and Burroughs Wellcome, including as Worldwide Therapeutic Head, Director, Oncology Clinical Development. Dr. Hohneker received his bachelor’s degree in chemistry from Gettysburg College and M.D. degree from the University of Medicine and Dentistry of New Jersey, Rutgers Medical School (Robert Wood Johnson Medical School). He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina Hospitals.

About Dimension Therapeutics, Inc.

Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. Dimension has two phase 1/2 clinical trials for the treatment of hemophilia B and OTC deficiency. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.

For more information, please visit www.dimensiontx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the development, preclinical and clinical results, and the continued progress of Dimension's portfolio and programs, including the initiation, timing, scope, or likelihood of regulatory filings and approvals, and our ability to develop and advance product candidates into, and successfully complete, clinical studies. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Dimension’s product candidates, including its candidates, DTX101 and DTX301, will not successfully be developed or commercialized in the times indicated or at all; and the risks described under the caption "Risk Factors" in Dimension Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Dimension Therapeutics’ additional filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Dimension Therapeutics undertakes no duty to update this information unless required by law.

Contacts:

Jean Franchi
Chief Financial Officer
Dimension Therapeutics
617-714-0709
jean.franchi@dimensiontx.com

Burns McClellan, on behalf of Dimension Therapeutics
Media: Justin Jackson
212-213-0006, ext.327
jjackson@burnsmc.com

Primary Logo

Dimension Therapeutics